SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker

Oncotarget

Volumn 5, Issue 5, 2014, Pages 1212-1225

  Kolukula, Vamsi K ^a   Sahu, Geetaram ^a   Wellstein, Anton ^a   Rodriguez, Olga C ^a   Preet, Anju ^a   Iacobazzi, Vito ^b   D'Orazi, Gabriella ^c,d   Albanese, Chris ^a   Palmieri, Ferdinando ^b   Avantaggiati, Maria Laura ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF BARI   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cancer; CIC; Citrate; FOXO 1; Marker; Mutant; P53 mutations; Prognosis; Prognostic; SLC25A1; Survival

Indexed keywords

CARRIER PROTEIN; CISPLATIN; PROTEIN P53; PROTEIN SLC25A1; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; ANION TRANSPORT PROTEIN; ANTINEOPLASTIC AGENT; BENZENE DERIVATIVE; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; SLC25A1 PROTEIN, HUMAN; TRICARBOXYLIC ACID; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; MUTANT; NONHUMAN; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CARCINOGENESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MUTATION; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR CELL LINE;

ANIMALS; ANION TRANSPORT PROTEINS; ANTINEOPLASTIC AGENTS; BENZENE DERIVATIVES; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICE; MITOCHONDRIAL PROTEINS; MUTATION; OVARIAN NEOPLASMS; PROGNOSIS; TRANSCRIPTION, GENETIC; TRICARBOXYLIC ACIDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84898657156     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1831     Document Type: Article

References (48)

1. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009; 137:413-31.
2. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012; 26:1268-86.
3. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013; 15:2-8.
4. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 2008; 22:1337-44.
5. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004; 119:861-2.
6. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-86Fraumeni syndrome. Cell.2004; 119:847-60.
7. Hanel W, Marchenko N, Xu S, Xiaofeng Yu S, Weng W, Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 2013; 7:898-8909
8. Lee MK, Teoh WW, Phang BH, Tong WM, Wang ZQ, Sabapathy K. Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. Cancer Cell. 2012; 22:751-64.
9. Freed-Pastor WA, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012; 148:244-58.
10. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G, Piaggio G. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell. 2006;10:191-202.
11. Palmieri F, Pierri CL. Mitochondrial metabolite transport. Essays Biochem. 2010; 47:37-52.
12. Palmieri F. Diseases caused by defects of mitochondrial carriers: a review. Biochim Biophys Acta. 2008; 1777:564-578.
13. Sun J, Aluvila S, Kotaria R, Mayor JA, Walters DE, Kaplan RS. Mitochondrial and Plasma Membrane Citrate Transporters: Discovery of Selective Inhibitors and Application to Structure/Function Analysis. Mol Cell Pharmacol. 2010; 2:101-110.
14. Catalina-Rodriguez O, Kolukula VK, Tomita Y, Preet A, Palmieri F, Wellstein A, Byers S, Giaccia AJ, Glasgow E, Albanese C, Avantaggiati ML. The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget. 2012 Oct;3(10):1220-35.
15. Bhalla K, Hwang BJ, Dewi RE, Ou L, Twaddel W, Fang HB, Vafai SB, Vazquez F, Puigserver P, Boros L, Girnun GD. PGC1a promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res. 2011; 21:6888-98.
16. Infantino V, Convertini P, Cucci L, Panaro MA, Di Noia MA, Calvello R, Palmieri F, Iacobazzi V. The mitochondrial citrate carrier: a new player in inflammation. Biochem J. 2011; 438: 433-436.
17. Nguyen H, Sankaran S, Dandekar S. Hepatitis C virus core protein induces expression of genes regulating immune evasion and anti-apoptosis in hepatocytes. Virology. 2006; 354:58-68.
18. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository Nucleic Acids Res. 2002; 30:207-10
19. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013; J41(Database issue):D991-5.
20. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles. Neoplasia. 2007; 9:166-180.
21. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, AksoyBA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 5:401-4.
22. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Sci Signal. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. 2013; 269:pl1.
23. Infantino V, Iacobazzi V, De Santis F, Mastrapasqua M, Palmieri F. Transcription of the mitochondrial citrate carrier gene: role of SREBP-1, upregulation by insulin and downregulation by PUFA. Biochem Biophys Res Commun. 2007; 356:249-254.
24. Choudhury S, Kolukula VK, Preet A, Albanese C, Avantaggiati ML. Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy? Cell Cycle. 2013; 12:1022-9.
25. Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, Reynoso K, Bargonetti J, Wellstein A, Albanese C, Avantaggiati ML. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle. 2012; 23:4436-46.
26. Perez RE, Knights CD, Sahu G, Catania J, Kolukula VK, Stoler D, Graessmann A, Ogryzko V, Pishvaian M, Albanese C, Avantaggiati ML. Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway. J Cell Physiol. 2010; 225:394-405.
27. Lee C, Huang CH. LASAGNA-Search: an integrated web tool for transcription factor binding site search and visualization. Biotechniques. 2013; 54:141-53.
28. Iacobazzi V, Infantino V, Bisaccia F, Castegna A, Palmieri F. Role of FOXA in mitochondrial citrate carrier gene expression and insulin secretion. Biochem Biophys Res Commun. 2009; 385:220-4.
29. Aluvila S, Sun J, Harrison DH, Walters DE, Kaplan RS. Inhibitors of the mitochondrial citrate transport protein: validation of the role of substrate binding residues and discovery of the first purely competitive inhibitor.Mol Pharmacol. 2010; 77:26-34.
30. Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003; 3:502-16.
31. Brachova P, Thiel KW, Leslie KK. The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci. 2013;14:19257-75.
32. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S, Nephew KP. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics. 2009; 2:34.
33. Peters D, Freund J, Ochs RL. Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther. 2005; 4:1605-16.
34. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725-31.
35. Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-7small-cell lung cancer, PLoS One. 2013; 8:e82241.
36. Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data of 1287 patients, Endocrine-Related Cancer. 2012; 19:197-208.
37. Dawid Walerych, Marco Napoli, Licio Collavin, Giannino Del Sal. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012; 33(11): 2007-2017.
38. Akira Mogi, Hiroyuki Kuwano TP53 Mutations in Nonsmall Cell Lung Cancer. J Biomed Biotechnol. 2011; 2011: 583929.
39. Mirza, A., Wu, Q., Wang, L., McClanahan, T., Bishop, W.R., Gheyas, F., Ding, W., Hutchins, B., Hockenberry, T., Kirschmeier, P., et al. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene. 2003; 22:3645-54.
40. Molchadsky A, Ezra O, Amendola PG, Krantz D, Kogan-36Sakin I, Buganim Y, Rivlin N, Goldfinger N, Folgiero V, Falcioni R, Sarig R, Rotter V. p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. Cell Death Differ. 2013; 20:774-83
41. Yecies JL, Manning BD. Chewing the fat on tumor cell metabolism. Cell. 2010; 140:28-30.
42. Edvardson S, Porcelli V, Jalas C, Soiferman D, Kellner Y, Shaag A, Korman SH, Pierri CL, Scarcia P, Fraenkel ND, Segel R, Schechter A, Frumkin A, Pines O, Saada A, Palmieri L, Elpeleg O. Agenesis of corpus callosum and optic nerve hypoplasia due to mutations in SLC25A1 encoding the mitochondrial citrate transporter. J Med Genet. 2013; 50:240-5.
43. Nota B, et al. Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2-and L-2-hydroxyglutaric aciduria. Am J Hum Genet. 2013;92:627-31.
44. Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochim Biophys Acta. 2009 May;1787(5):414-20.
45. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer. 2009 Oct;9(10):691-700.
46. Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle. 2010; 9:1091-6.
47. Van der Horst A, Burgering BM.Stressing the role of FoxOproteins in lifespan and disease. Nat Rev Mol Cell Biol. 2007 Jun;8(6):440-50.
48. Schramek D, Sendoel A, Segal JP, Beronja S, Heller E, Oristian D, Reva B, Fuchs E. Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science. 2014; 343:309-13.